First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

NCT05920135 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR Mutant Advanced Non-Small Cell Lung Cancer

Interventions

DRUG: BBT-207

Sponsor

Bridge Biotherapeutics, Inc.